<?xml version="1.0" encoding="UTF-8"?>
<p>As more asymptomatic patients are started on ART, treatment goals will require more robust and durable first-line regimens to prevent the development and transmission of drug resistance.
 <xref rid="dkx118-B17" ref-type="bibr">
  <sup>17</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B18" ref-type="bibr">
  <sup>18</sup>
 </xref> The mainstay of treatment is two NRTIs with a third core agent from one of the NNRTI, boosted PI or integrase strand transfer inhibitor (INSTI) drug classes.
 <xref rid="dkx118-B19" ref-type="bibr">
  <sup>19</sup>
 </xref> In developing countries, rates of virological failure (40%) and transmitted drug resistance (5%–16%) are rising, related to the use of thymidine analogues, particularly stavudine and zidovudine, and NNRTIs.
 <xref rid="dkx118-B18" ref-type="bibr">
  <sup>18</sup>
 </xref>
 <sup>,</sup>
 <xref rid="dkx118-B20" ref-type="bibr">
  <sup>20–24</sup>
 </xref>
</p>
